Concurrent Investment Advisors LLC Has $13.32 Million Position in Merck & Co., Inc. (NYSE:MRK)

Concurrent Investment Advisors LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 117,290 shares of the company’s stock after purchasing an additional 4,229 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $13,319,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in MRK. China Universal Asset Management Co. Ltd. boosted its position in Merck & Co., Inc. by 10.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 55,281 shares of the company’s stock worth $7,332,000 after purchasing an additional 5,088 shares during the last quarter. Quent Capital LLC lifted its position in shares of Merck & Co., Inc. by 11.4% during the first quarter. Quent Capital LLC now owns 10,236 shares of the company’s stock worth $1,351,000 after acquiring an additional 1,048 shares in the last quarter. Commerce Bank boosted its stake in Merck & Co., Inc. by 0.8% in the 1st quarter. Commerce Bank now owns 1,307,875 shares of the company’s stock worth $172,574,000 after purchasing an additional 10,991 shares during the period. Etfidea LLC purchased a new stake in Merck & Co., Inc. in the 1st quarter worth approximately $202,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its position in shares of Merck & Co., Inc. by 36.2% during the 1st quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 5,088 shares of the company’s stock valued at $671,000 after purchasing an additional 1,353 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

NYSE:MRK traded up $0.26 during mid-day trading on Wednesday, hitting $101.91. 1,915,207 shares of the company’s stock traded hands, compared to its average volume of 8,816,787. Merck & Co., Inc. has a 1 year low of $98.60 and a 1 year high of $134.63. The company has a market cap of $258.12 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.46 and a beta of 0.40. The firm’s 50 day simple moving average is $111.71 and its 200 day simple moving average is $120.47. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The company had revenue of $16.66 billion for the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 37.32% and a net margin of 19.23%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $2.13 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 7.75 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, October 3rd. Barclays cut their price target on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday, October 7th. BMO Capital Markets reduced their price target on shares of Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Sanford C. Bernstein assumed coverage on Merck & Co., Inc. in a research note on Thursday, October 17th. They set a “market perform” rating and a $115.00 price objective on the stock. Finally, Truist Financial cut their target price on shares of Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $129.93.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.